Nonalcoholic steatohepatitis, along with other forms of nonalcoholic fatty
liver disease, is a chronic liver disease that is attracting increasing sig
nificance. It is a clinicopathologic syndrome that was originally described
in obese, diabetic females who denied alcohol use but in whom the hepatic
histology was consistent with alcoholic hepatitis. This typical patient pro
file has been expanded and is now recognized to occur even in normal weight
males without overt abnormalities in carbohydrate metabolism. Although ori
ginally believed to be a benign clinical entity, nonalcoholic steatohepatit
is is now recognized as a cause of progressive fibrotic liver disease with
adverse clinical sequelae. It is important to emphasize that nonalcoholic s
teatohepatitis is best considered one type of a larger spectrum of nonalcoh
olic fatty liver disease that is a consequence of insulin resistance and ra
nges from fat alone to fat plus inflammation, fat plus ballooning degenerat
ion, and nonalcoholic steatohepatitis, the latter being the most serious fo
rm. As with any disease, the clinical importance of nonalcoholic steatohepa
titis is related to its prevalence and natural history. Recent studies usin
g different methodologies indicate that in the general population the preva
lence of fatty liver and nonalcoholic steatohepatitis is approximately 20%
and 3%, respectively. These prevalence rates are increased in certain subpo
pulations such as obesity and type II diabetes. Of greater concern is the r
ecognition that cirrhosis and liver-related deaths occur in approximately 2
0% and 8% of these patients, respectively, over a 10-year period. Risk fact
ors for these adverse clinical symptoms include patients older than the age
of 45, the presence of diabetes or obesity, an aspartate aminotransferase/
alanine aminotransferase ratio >1 and hepatic histology. However, a number
of important unresolved issues must be clarified before the true natural hi
story of this disease can be fully understood.